Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Small Cell Lung Cancer (SCLC)

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed small cell lung cancer (SCLC)

- Must have received at least one prior course of standard chemotherapy and, if
indicated, up to 6,900 cGy of thoracic radiotherapy

- Patients who received prior radiotherapy must show evidence of progressive
disease

- Patients who received no prior radiotherapy to the primary tumor must show
evidence of stable or progressive disease

- Measurable disease

- Must have evidence of carcinoembryonic antigen (CEA) production or expression
documented by one of the following:

- Serum CEA at least 10 ng/mL

- Positive immunohistology of either the primary tumor or a metastasis with CEA
specific monoclonal antibody

- Must have unilateral bone marrow biopsy with less than 25% tumor involvement

- No known, active brain metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 70-100%

- ECOG 0-2

Life expectancy:

- At least 3 months

Hematopoietic:

- WBC at least 3,000/mm^3

- Granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin no greater than 2 mg/dL

- AST no greater than 2 times upper limit of normal (ULN)

- No hepatitis B or C

- No other serious liver abnormality

Renal:

- Creatinine no greater than 1.5 times ULN

- No urinary incontinence

Cardiovascular:

- Ejection fraction at least 50%

Pulmonary:

- FEV_1 and FVC at least 60%

- DLCO at least 50% predicted

Other:

- No severe anorexia, nausea, or vomiting

- No other significant medical problems

- No prisoners

- No reactivity to humanized MN-14 (in patients with prior exposure to chimeric or
humanized antibody)

- HIV negative

- No active HIV-related disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 3 months
following study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- See Chemotherapy

- No concurrent growth factors (e.g., filgrastim [G-CSF])

Chemotherapy:

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy

- No prior high dose chemotherapy with stem cell transplantation

Endocrine therapy:

- Not specified

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy

- Prior radiotherapy to less than 30% of red marrow (including standard chest x-ray for
limited stage SCLC) allowed

Surgery:

- At least 4 weeks since prior major surgery